Aziz Kabeer 4

What Happened

• Aziz Kabeer, a member of AN2 Therapeutics' board of directors, was issued 2,852 shares on 2026-07-10 as an award/compensation. The filing reports an acquisition price of $0.00, giving a reported transaction value of $0. These shares were issued in lieu of cash compensation and vested immediately.

Key Details

• Transaction date: 2026-07-10; Price per share: $0.00; Shares acquired: 2,852; Reported value: $0.
• Filing date: 2026-07-10 (same day as the transaction in the Form 4).
• Vesting/tax note: Footnote F1 — shares issued in lieu of cash compensation under the non-employee director policy; all shares vest immediately.
• Related holdings: Footnotes F2 and F3 disclose that certain AN2 shares are held by Adjuvant entities (Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.). Kabeer is Secretary of the managing entity and may be deemed to share voting/dispositive power over those fund-held securities; those entities disclaim beneficial ownership except for pecuniary interest.
• Shares owned after the transaction: Not specified in the filed report.

Context

• This was a compensation award (code A) rather than a market purchase or sale; awards issued in lieu of cash are routine for non-employee directors and do not necessarily signal the director’s market view. Immediate vesting means the shares are not subject to future service-based vesting conditions.